Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03VCF
|
|||
| Former ID |
DIB005224
|
|||
| Drug Name |
Urtoxazumab
|
|||
| Synonyms |
TMA-15; Anti shiga-like toxin 2 humanized MAb, Teijin; HuVTm1.1.1; Anti-SLT-2 humanized MAb (E coli infection), Teijin
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Escherichia coli infection [ICD-11: 1A03; ICD-10: A04, A04.4] | Discontinued in Phase 2 | [1] | |
| Company |
Teijin Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Enterobacteria Shiga-like toxin 2B (EntBac stxB2) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021716) | |||
| REF 2 | Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother. 2010 Jan;54(1):239-43. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.